Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Regeneron's (REGN) Updated Linvoseltamab Data Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also. | May 25, 2023
FN Media Group Presents USA News Group News Commentary VANCOUVER, BC, Jan. 27, 2022 /PRNewswire/ USA News Group - There's plenty of optimism surrounding the major medical breakthroughs
/PRNewswire/ Includes latest data for REGN5458, including in highest dose levels (200-800 mg) Among patients who responded across all dose groups (3-800.